Lipoprotein particle subclasses, cardiovascular disease and HIV infection

Atherosclerosis

Volumn 207, Issue 2, 2009, Pages 524-529

  Duprez, Daniel A ^a   Kuller, Lewis H ^b   Tracy, Russell ^c   Otvos, James ^d   Cooper, David A ^e   Hoy, Jennifer ^f   Neuhaus, Jacqueline ^a   Paton, Nicholas I ^g   Friis Moller, Nina ^h   Lampe, Fiona ⁱ   Liappis, Angelike P ^j   Neaton, James D ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c UNIVERSITY OF VERMONT   (United States)

^d LIPOSCIENCE INC   (United States)

^e UNIVERSITY OF NEW SOUTH WALES   (Australia)

^f MONASH UNIVERSITY   (Australia)

^g MEDICAL RESEARCH COUNCIL   (United Kingdom)

^h UNIVERSITY OF COPENHAGEN   (Denmark)

ⁱ UNIVERSITY COLLEGE LONDON   (United Kingdom)

^j VETERANS AFFAIRS MEDICAL CENTER   (United States)

more..

Author keywords

Atherosclerosis; Cardiovascular disease; Cholesterol; HDL and LDL cholesterol; HIV; Ischemic heart disease; Lipids; Lipoprotein particle size and number

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTIRETROVIRUS AGENT; C REACTIVE PROTEIN; D DIMER; HIGH DENSITY LIPOPROTEIN; INTERLEUKIN 6; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; VERY LOW DENSITY LIPOPROTEIN;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CASE CONTROL STUDY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG INTERMITTENT THERAPY; FEMALE; HIGH RISK PATIENT; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VIRUS INHIBITION;

ADULT; ANTI-RETROVIRAL AGENTS; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; DRUG ADMINISTRATION SCHEDULE; FEMALE; HIV INFECTIONS; HUMANS; LIPOPROTEINS, HDL; LOGISTIC MODELS; MALE; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE, BIOMOLECULAR; ODDS RATIO; PARTICLE SIZE; RISK ASSESSMENT; RISK FACTORS;

EID: 70450186915     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2009.05.001     Document Type: Article

References (19)

1. Palella Jr. F.J., Delaney K.M., Moorman A.C., et al. Declining morbidity and mortality among patients with advanced immunodeficiency virus infection. N Engl J Med 338 (1998) 853-860
2. Obel N., Thomsen H.F., Kronborg G., et al. Ischemic heart disease in HIV-infected and HIV-uninfected individuals: a population-based cohort study. Clin Infect Dis 44 (2007) 1625-1631
3. Grunfeld C., Kotler D.P., Arnett D.K., et al. Contribution of metabolic and anthropometric abnormalities to cardiovascular disease risk factors. Circulation 118 (2008) e20-e28
4. Strategies for Management of Antiretroviral Therapy (SMART) Study Group, El-Sadr W.M., Lundgren J.D., Neaton J.D., et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 355 (2006) 2283-2296
5. Phillips A.N., Carr A., Neuhaus J., et al. Interruption of antiretroviral therapy and risk of cardiovascular disease in persons with HIV-1 infection: exploratory analyses from the SMART trial. Antivir Ther 13 (2008) 177-187
6. Oh J., and Hegele R.A. HIV-associated dyslipidaemia: pathogenesis and treatment. Lancet Infect Dis 7 (2007) 787-796
7. Asztalos B.F., Schaefer E.J., Horvath K.V., et al. Protease inhibitor-based HAART, HDL, and CHD-risk in HIV-infected patients. Atherosclerosis 184 (2006) 72-77
8. Riddler S.A., Li X., Otvos J., et al. Antiretroviral therapy is associated with an atherogenic lipoprotein phenotype among HIV-1-infected men in the Multicenter AIDS Cohort Study. J Acquir Immune Defic Syndr 48 (2008) 281-288
9. Jeyarajah E.J., Cromwell W.C., and Otvos J.D. Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy. Clin Lab Med 26 (2006) 847-870
10. Kuller L., Arnold A., Tracy R., et al. Nuclear magnetic resonance spectroscopy of lipoproteins and risk of coronary heart disease in the cardiovascular health study. Arterioscler Thromb Vasc Biol 22 (2002) 1175-1180
11. Otvos J.D., Collins D., Freedman D.S., et al. Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events andare favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial. Circulation 113 (2006) 1556-1563
12. Kuller L.H., Tracy R., Belloso W., et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 5 (2008) e203
13. Kuller L.H., Grandits G., Cohen J.D., Neaton J.D., Prineas R., and Multiple Risk Factor Intervention Trial Research Group. Lipoprotein particles, insulin, adiponectin, C-reactive protein and risk of coronary heart disease among men with metabolic syndrome. Atherosclerosis 195 (2007) 122-128
14. Rosenson R.S., Otvos J.D., and Freedman D.S. Relations of lipoprotein subclass levels and low-density lipoprotein size to progression of coronary artery disease in the pravastatin limitation of atheroscleroisis in the coronary arteries (PLAC-1) trial. Am J Cardiol 90 (2002) 89-94
15. Blake G.J., Otvos J.D., Rifai N., and Ridker P.M. Low-density lipoprotein particle concentration and size as determined by nuclear magnetic resonance spectroscopy as predictors of cardiovascular disease in women. Circulation 106 (2002) 1930-1937
16. Tabet F., and Rye K.A. High-density lipoproteins, inflammation and oxidative stress. Clin Sci 116 (2009) 87-98
17. Rose H., Hoy J., Woolley I., et al. HIV infection and high density lipoprotein metabolism. Atherosclerosis 199 (2008) 79-86
18. Wilson P.W.F. Evidence of systemic inflammation and estimation of coronary artery disease risk: a population perspective. Am J Med 121 Suppl 1 (2008) S15-S20
19. Rader D.J. Molecular regulation of HDL metabolism and function: implications for novel therapies. J Clin Invest 116 (2006) 3090-3100